Journal
ANTIVIRAL RESEARCH
Volume 215, Issue -, Pages -Publisher
ELSEVIER
DOI: 10.1016/j.antiviral.2023.105638
Keywords
SARS-CoV-2; Omicron variants; Monoclonal antibody; Sotrovimab; Hamster model
Categories
Ask authors/readers for more resources
The emergence of SARS-CoV-2 Omicron variants has changed the use of therapeutic monoclonal antibodies. In vitro studies showed that only Sotrovimab has partial activity against BQ.1.1 and XBB.1. In a hamster model study, it was found that Sotrovimab remains active against BQ.1.1 and XBB.1 at human exposure levels, but with lower efficacy against BQ.1.1 compared to the globally dominant Omicron sublineages BA.1 and BA.2.
The successive emergence of SARS-CoV-2 Omicron variants has completely changed the modalities of use of therapeutic monoclonal antibodies. Recent in vitro studies indicated that only Sotrovimab has maintained partial activity against BQ.1.1 and XBB.1. In the present study, we used the hamster model to determine whether Sotrovimab retains antiviral activity against these Omicron variants in vivo. Our results show that at exposures consistent with those observed in humans, Sotrovimab remains active against BQ.1.1 and XBB.1, although for BQ.1.1 the efficacy is lower than that observed against the first globally dominant Omicron sublineages BA.1 and BA.2.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available